Exelixis Inc

NASDAQ:EXEL   3:59:54 PM EDT
16.96
-0.27 (-1.57%)
Products, Litigation

Exelixis Says In May, Got Notice Letters From Teva Regarding ANDA Teva Submitted To FDA

Published: 06/21/2021 21:41 GMT
Exelixis Inc (EXEL) - Exelixis- in May, Got Notice Letters From Teva Regarding Anda Teva Submitted to FDA, Requesting Approval to Market Generic Version of Cabometyx Tablets.
Exelixis Inc - on June 17, Filed Complaint in United States District Court for District of Delaware for Patent Infringement Against Teva.
Exelixis Inc - Teva's Notice Letters Included Paragraph Iv Certifications With Respect to Our U.S. Patent Nos.
9,724,342 and 10,034,873.
Exelixis Inc - Teva's Notice Letters Did Not Provide Notice of a Paragraph Iv Certification Against Any Additional Cabometyx Patents.
Exelixis Inc - Exelixis is Seeking Equitable Relief Enjoining Teva From Infringing Patents.
Exelixis - Seeking Order That Effective Date of Any FDA Approval of Teva’s Anda Be No Earlier Than Expiration of All of Exelixis' 3 U.S. Patents.